ACA
TEVA icon

Atlas Capital Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Atlas Capital Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$930K Buy
27,453
+3,479
+15% +$116K 0.1% 177
2026
Q1 		$722K Sell
23,974
-7,970
-25% -$256K 0.08% 192
2025
Q4 		$997K Buy
+31,944
New +$787K 0.11% 153
2025
Q2 		$593K Sell
35,374
-662
-2% -$10.7K 0.07% 221
2025
Q1 		$554K Sell
36,036
-5,004
-12% -$89.4K 0.07% 238
2024
Q4 		$905K Sell
41,040
-2,079
-5% -$37.8K 0.11% 153
2024
Q3 		$777K Sell
43,119
-772
-2% -$13.5K 0.12% 154
2024
Q2 		$713K Buy
43,891
+149
+0.3% +$2.29K 0.09% 176
2024
Q1 		$617K Buy
43,742
+42,502
+3,428% +$536K 0.1% 188
2023
Q4 		$12.9K Hold
1,240
– – ﹤0.01% 725
2023
Q3 		$12.6K Hold
1,240
– – ﹤0.01% 683
2023
Q2 		$9.34K Sell
1,240
-20,687
-94% -$168K ﹤0.01% 743
2023
Q1 		$194K Hold
21,927
– – 0.03% 360
2022
Q4 		$200K Hold
21,927
– – 0.03% 339
2022
Q3 		$177K Buy
21,927
+9,250
+73% +$81.8K 0.03% 360
2022
Q2 		$95.3K Hold
12,677
– – 0.02% 470
2022
Q1 		$119K Buy
12,677
+1,987
+19% +$16.6K 0.02% 446
2021
Q4 		$85.6K Buy
10,690
+2,669
+33% +$24.1K 0.01% 474
2021
Q3 		$78.1K Hold
8,021
– – 0.01% 469
2021
Q2 		$79.4K Hold
8,021
– – 0.01% 477
2021
Q1 		$92.6K Sell
8,021
-4,455
-36% -$51.1K 0.02% 425
2020
Q4 		$120K Hold
12,476
– – 0.03% 371
2020
Q3 		$112K Hold
12,476
– – 0.03% 304
2020
Q2 		$154K Sell
12,476
-625
-5% -$7.07K 0.04% 348
2020
Q1 		$118K Buy
13,101
+13,029
+18,096% +$133K 0.04% 346
2019
Q4 		$705 Hold
72
– – ﹤0.01% 624
2019
Q3 		$495 Sell
72
-7,020
-99% -$53.8K ﹤0.01% 630
2019
Q2 		$65.5K Sell
7,092
-25,551
-78% -$308K 0.02% 446
2019
Q1 		$512K Sell
32,643
-560
-2% -$9.88K 0.18% 148
2018
Q4 		$512K Buy
33,203
+7,139
+27% +$146K 0.21% 133
2018
Q3 		$563K Sell
26,064
-9,513
-27% -$221K 0.19% 145
2018
Q2 		$823K Sell
35,577
-2,771
-7% -$56.5K 0.29% 99
2018
Q1 		$655K Buy
+38,348
New +$749K 0.2% 161

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Atlas Capital Advisors's TEVA Position: Q2 2026 in Review

Atlas Capital Advisors increased its Teva Pharmaceuticals (TEVA) stake by 15% in Q2 2026, buying an estimated $116K and bringing the position to 27,453 shares worth $930K. The position accounts for 0.1% of the portfolio, ranked #177.

Atlas Capital Advisors first reported a position in TEVA in Q1 2018 and has held it in 33 quarters since. The position peaked at $997K in Q4 2025. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Atlas Capital Advisors held 27,453 shares of Teva Pharmaceuticals worth $930K as of Q2 2026.
  • Atlas Capital Advisors bought 3,479 Teva Pharmaceuticals shares in Q2 2026, an estimated $116K.
  • Teva Pharmaceuticals made up 0.1% of Atlas Capital Advisors's portfolio in Q2 2026, its #177 holding.
  • Atlas Capital Advisors first reported a position in Teva Pharmaceuticals in Q1 2018 and has held it in 33 quarters since.
  • Atlas Capital Advisors's Teva Pharmaceuticals position peaked at $997K in Q4 2025.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Atlas Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.